Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|December 19, 2020
SLFN11 informs on standard of care and novel treatments in a wide range of cancer modelsClaudia Winkler, Joshua Armenia, Gemma N Jones, et al.
Oncotarget|January 18, 2018
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyJustin Greene, Anna Nguyen, Stacey M Bagby, et al.
Molecular Cancer Therapeutics|September 20, 2019
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses PreclinicallyLucy C Riches, Antonio G Trinidad, Gareth Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I StudyTimothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
British Journal of Cancer|November 3, 2018
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistryGemma N Jones, Claire Rooney, Nicola Griffin, et al.
Cancer Medicine|April 3, 2021
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancerJohanne I Weberpals, Trevor J Pugh, Paola Marco-Casanova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 5, 2012
Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approachDafni Moschidou, Sayandip Mukherjee, Michael P Blundell, et al.
British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.
Lancet (London, England)|January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trialStephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
The Journal of Clinical Investigation|November 7, 2023
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammationMagnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.
Pageof 3